Fritextsökning
Artiklar per år
Innehållstyper
-
Roche sänker budet på Genentech
I juli ifjol var budet 89 dollar per aktie. Då sa Genentechs styrelse nej tack. Nu meddelar läkemedelsjätten att man sänker budet och vänder sig direkt till småägarna.
-
Lunds nya rektor har tillträtt
Nu är han på plats. Vinnovas förre generaldirektör tar över rodret vid Lunds universitet.
-
Hårt tryck på Läkemedelsverket
Alltför många vill ansöka om Sverige som referensland i den decentraliserade processen för att godkänna läkemedel. Idag införs nya rutiner för att hantera situationen.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Top modern lab to Sahlgrenska
The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.
-
Oasmia gets a confirmation
FDA has granted Oasmia an expedited review status for Paclical Vet.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
Woman deficit in Swedish research
The IP firm Awapatent will soon launch its Innovation Barometer 2009. This year Awapatent reveals that the statistics is even worse, compared to last year.
-
Harmony prevents dementia
People who are active, outgoing and relaxed may be less likely to develop dementia, according to a new study from Karolinska Institutet.
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
-
Positive combined cancer therapy
Topotarget announces positive data with new treatment against colorectal cancer.
-
Abbott expands by acquisition
An acquisition gives Abbott a leadership position in another large and growing medical device segment.
-
Pharma is a safe market
Pharma is the best industry to invest in. That states leaders from risk capital companies, interviewed by the Economist Intelligence Unit.
-
Vitrolife wants to acquire Medicult
The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Medicult acquires embryo scanner
The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.
-
Collaboration brings next generation drugs
Wyeth and Santaris Pharma announce a new alliance to develop RNA-based medicines.
-
Bio-Linux goes global
Recently the NEBC Bio-Linux Version 5.0 was released, a one-stop shop for bioinformatics tools in a Linux context.
-
Elekta gets ok from China
The Swedish medtech comapny Elekta has received approval from the Chinese authority State Food and Drug Administration, SFDA, to sell its linear accelerator in China.
-
Danish biorefinery can save US billions
The Danish Inbicon biorefinery process could save the US billions on foreign oil, the organization states.